Barcelona

• Ziftomenib in combination with chemotherapy for children with relapsed/refractory acute leukemia Recruiting
  2023-505262-28-00 3 2025-03-24 Acute Myeloid Leukemia
• Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants with Locally Advanced or Metastatic Cholangiocarc … Recruiting
  2024-514261-19-00 9 2025-03-24 Locally advanced, unresectable or metastatic cholangiocarcinoma with a
• A Phase 1a/b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of PRMT5 I … Recruiting
  2024-515307-19-00 1 2025-03-24 Advanced, or metastatic solid tumors with methylthioadenosine phosphor
• Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast C … Recruiting
  2024-515445-42-00 5 2025-03-24 Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast
• Phase I Study of PM54 Administered to Patients with Advanced Solid Tumors Recruiting
  2024-517579-19-00 3 2025-03-24 Selected Advanced Solid Tumors
• A safety and efficacy study of RTX001 autologous macrophage therapy in participants with decompensated liver cirrhosis Recruiting
  2024-516288-10-00 9 2025-03-21 Liver Cirrhosis
• Ph 1 Study of ORIC-944 in Patients with Metastatic Prostate Cancer. Recruiting
  2024-515527-11-00 1 2025-03-20 Prostate cancer
• A clinical study of zilovertamab vedotin in people with large B-cell lymphoma (MK-2140-010) Recruiting
  2024-515566-13-00 5 2025-03-19 Diffuse Large B-Cell Lymphoma (DLBCL)
• A study to measure how well seltorexant works in adult depressed patients and how safe it is both for short- and long-term use when taken wi … Recruiting
  2023-509070-36-00 5 2025-03-18 Major Depressive Disorder with Insomnia Symptoms
• KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors Recruiting
  2024-513285-19-00 1 2025-03-14 Pancreatic Ductal Adeno Carcinoma
• A Phase I/II with Ruxolitinib in Patients with Myelofibrosis (MF) who are Unresponsive to JAK inhibitors (HEMA-MED) Recruiting
  2024-515252-20-00 9 2025-03-14 Myelofibrosis (MF) unresponsive to JAK inhibitors
• Study to evaluate efficacy and safety of inclisiran in children aged 6 to under 12 years of age with heterozygous familial hypercholesterole … Recruiting
  2024-514594-21-00 5 2025-03-13 Heterozygous Familial Hypercholesterolemia
• Multicenter, open label, single arm, phase II study to assess the efficay and safety of enfortumab-vedotin (EV) as a single agent in patient … Recruiting
  2024-515511-21-00 4 2025-03-13 Neuroendocrine Carcinoma / G3 Neuroendocrine Tumours
• A clinical study of MK-6070 and ifinatamab deruxtecan in people with small cell lung cancer (MK-6070-002) Recruiting
  2024-517926-25-00 9 2025-03-12 Small cell lung cancer
• A clinical study of MK-0472 in people with solid tumors (MK-0472-001) Recruiting
  2024-516006-32-00 1 2025-03-11 Malignant Neoplasm - Solid Tumors
• A study to assess the efficacy and safety of lumateperone in patients with major depressive disorder Recruiting
  2023-503836-41-00 5 2025-03-10 Major Depressive Disorder
• Lutathera for the treatment of recurrent Meningioma (LUMEN-1) Recruiting
  2024-513443-93-00 4 2025-03-10 Recurrent Meningioma without local treatment options (Surgery or Radio
• A Study of Orally Administered MOMA-313 in Participants with Advanced or Metastatic Solid Tumours Recruiting
  2024-513502-62-00 1 2025-03-07 Advanced or Metastatic Solid Tumors
• A trial to learn if AZD0486 alone or with other anticancer drugs is safe and works in adults with certain blood cancers Recruiting
  2024-515034-33-00 9 2025-03-05 Mantle Cell Lymphoma
• CD8 PET imaging in metastatic solid tumours; A phase II, open label, multi-center study of 89Zr-DF-crefmirlimab for CD8 positron emission to … Recruiting
  2024-515885-15-00 9 2025-03-04 Patients with metastatic solid tumours, where clinical data has shown
• Study of MK-5684-based Therapies in Advanced Prostate Cancer Recruiting
  2023-506288-33-00 9 2025-03-03 Metastatic castration resistant prostate cancer (mCRPC)
• KEYMAKER U01 Sub-Study E Signal-finding study to test investigational agents with pembrolizumab in combination with chemotherapy in newly di … Recruiting
  2023-509234-19-00 4 2025-03-03 Participants With Newly Diagnosed Resectable Stages II-IIIB (N2) Non-s
• A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept Recruiting
  2024-516380-81-00 4 2025-02-28 Treatment of IgAN
• A Phase 3 Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants with Juveni … Recruiting
  2024-517262-41-00 5 2025-02-28 Juvenile Psoriatic Arthritis (JPsA)

Showing 1,081–1,104 of 3,391 trials